Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotech Startup Investors in United States in January 2026

Last updated: Jan 2026 A list of 50 angel investors and VC (Venture Capital) funds that invest in Biotech startups based in United states. We rank investors based on the number of investments they made in Biotech companies from United states. We update this investor list every month.

Top 50 Biotech Startup Investors in United States in January 2026

Investor	Biotech United States investments
SOSV	124
ARCH Venture Partners	116
Alexandria Venture Investments	94
OrbiMed	79
Atlas Venture	70
New Enterprise Associates	66
Versant Ventures	64
Polaris Partners	62
Innova Memphis	62
Khosla Ventures	61
MPM Capital	60
5AM Ventures	60
Third Rock Ventures	60
RA Capital Management	55
F-Prime	54
BioAdvance	49
Canaan Partners	48
The Column Group	45
Andreessen Horowitz	44
KdT Ventures	43
Novartis Venture Fund	43
Alumni Ventures	41
Connecticut Innovations	41
Lux Capital	41
Fifty Years	41
Google Ventures	40
DCVC	40
Hatteras Venture Partners	39
Dolby Family Ventures	38
Frazier Healthcare Partners	38
Pfizer Venture Investments	37
Sofinnova Investments	36
Mission BioCapital	36
Life Science Angels	35
Northpond Ventures	35
Civilization Ventures	34
Boston Harbor Angels	34
Domain Associates	33
Amgen Ventures	33
Refactor	32
Novo Holdings	32
Founders Fund	32
Omega Funds	31
North Carolina Biotechnology Center	31
Takeda Ventures	31
Vivo Capital	30
Flagship Pioneering	30
DCVC Bio	30
Eli Lilly	30
Casdin Capital	29

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, United Kingdom

Portfolio highlights

Paradigm — Paradigm is building a platform that enables equitable access to clinical trials while enhancing efficiency and improving ease of use for providers.
Basking Biosciences — Basking Biosciences is a startup that’s developing a therapy to restore blood flow to the brain during ischemic stroke, preventing hemorrhage and long-term damage.
Soufflé Therapeutics — Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology.

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Canada, France

Portfolio highlights

Tr1x — Tr1x develops cellular therapies intended for the treatment of autoimmune disorders.
Affinia Therapeutics — Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines for people.
Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

TandemAI — Streamline discovery with our integrated drug discovery platform, blending AI, physics-based tools, and wet lab for unparalleled innovation. Click now.
Epigenic Therapeutics — Epigenic Therapeutics is a biotech firm that offers gene editing therapy.
Pionyr Immunotherapeutics — Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, isdesigned to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Sionna Therapeutics — Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).
Matchpoint Therapeutics — Matchpoint aims to discover and develop precision small molecules that harness the power of covalency to bring new possibilities to the treatment of serious immune disease and cancer.

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Series C
United States, India, United Kingdom

Portfolio highlights

Wizard — Join the world's leading businesses using Wizard to sell, market, and engage their customers via text.
Immunomedics — Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company. The company was founded in 1982 and headquartered in Morris Plains, New Jersey.
Willow — Willow is a female technology company that develops an in-bra wearable breast pump. Its breast pumps are cordless and spill-proof. It also tracks milk output through a mobile application along with an online portal, enabling mothers to pump anywhere without hassle. The company was founded in 2014 and is headquartered in Mountain View, California.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Standard BioTools — Standard BioTools delivers leading genomic and proteomic solutions. Discover CyTOF, Hyperion, and Biomark technologies for deep biological insights.
Rennovia — Rennovia, Inc. produces renewable chemicals. It offers adipic acids and adiponitrile for consumer-end products, including carpets, heat-resistant automotive parts, furniture, apparel, footwear, luggage, adhesives, and coatings. Rennovia was incorporated in 2009 and is based in Menlo Park, California.
Alexza Pharmaceuticals — Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. It was founded in 2001 and headquartered in Mountain View, California.

Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series A, Series C
United States, Ireland, Singapore

Portfolio highlights

Jnana Therapeutics — Jnana was founded by leading academic scientists, drug developers and investors to develop medicines that transform the lives of patients.
Phreesia — Phreesia is a privately held company focused on patient check-in. The company replaces the outdated patient clipboard in physician offices with a free wireless touch screen and swipe card enabled PhreesiaPad. Phreesia automates the patient check-in process by collecting personal health information on the PhreesiaPad from the patient in a secure andHIPAA-compliant fashion. The product is designed to interface with physicians' existing and future technology and is compatible with electronic medical records (EMRs)Phreesia does not require any changes to the physician workflow and captures comprehensive patient information that can automatically be printed to reports for administrative and clinical staff. The company also improves the patient experience by better preparing them for their appointments, offering up-to-date health education relevant to their medical concerns, and enabling them to verify, rather than re-enter, information recorded at previous visits to the medical practice. The company draws on the expertise of a leading Medical Advisory Board and has initiated a series of patient care initiatives that concentrate on both wellness and disease prevention. The company is backed by premier venture capital firms and has received $13.25 million in financing to date.
Thirty Madison — Thirty Madison is a human-first healthcare company, powering access to affordable specialized healthcare through brands like Keeps and Cove.

Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.

Investment focus

Health Care, Medical, Medical Device
Seed, Pre-Seed, Funding Round
United States, Argentina, United Kingdom

Portfolio highlights

HerdDogg — HerdDogg is passionate about livestock. Its innovative data platform sits at the intersection of agtech, the internet of things, and global food security. Our patented DoggTags and DoggBone, together with our Animal Traceability Platform, help producers make more money from every animal they raise. The HerdDogg system enables animal tracking,welfare monitoring and traceability in an easy-to-use application. For more information, visit herddogg.com.
Rescue Forensics — Customer service is our #1 priority. Get a premium domain for your website today. Financing available.
Soiltech Wireless — Soiltech Wireless is a developer of ag-tech solutions to design electronic devices for agricultural professionals. Its product provides real-time data to drive efficiency and optimize quality. It also provides actionable data without installation hassles and creates scalable monitoring solutions for farmers.The company was founded in 2019 and isheadquartered in Rupert, Idaho.

Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.

Investment focus

Software, Artificial Intelligence, Health Care
Series A, Series B, Seed
United States, India, United Kingdom

Portfolio highlights

Periodic Labs — Periodic Labs develops artificial intelligence systems that simulate and predict the properties of materials using machine learning. The company applies computational models to support the discovery and design of materials used in sectors such as energy, electronics, and infrastructure. It builds tools that aim to reduce the time and costassociated with traditional research and development processes. Periodic Labs uses AI to analyze large-scale scientific data and collaborates with academic and industry partners to support material science research.
Vectra AI — Vectra is the world leader in AI threat detection and response. The Cognito platform uses AI to detect attackers in real time and perform conclusive investigations.
Point One Navigation — Precise Positioning for the next generation of transportation. 10cm accuracy everywhere.

Powering Breakthroughs in Life Sciences

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Series C
United States, Canada, United Kingdom

Portfolio highlights

Syndax Pharmaceuticals — Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
Portola Pharmaceuticals — As Alexion, AstraZeneca Rare Disease, we are delivering life-changing therapies to people living with rare diseases.
Rhythm Pharmaceuticals — Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Fellow Health — Fellow provides peer-reviewed, clinically valid, mail-in semen analysis for clinics looking for improved compliance and a patient-friendly solution to fertility testing.
Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
CAMP4 Therapeutics — CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients.

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
Jounce Therapeutics — Concentra is a biosciences company.
Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Post-IPO Equity
United States, United Kingdom, Canada

Portfolio highlights

Star Therapeutics — Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Triana Biomedicines — Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.
Alchemab Therapeutics — Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.

F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Series C
United States, United Kingdom, China

Portfolio highlights

iRiva Medical — iRiva Medical is developing novel neuromodulation therapies to address unmet therapeutic requirements in large patient populations.
K36 Therapeutics — K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
Canary Technologies — Use Canary to securely conduct contactless check-in and process credit card authorizations, contracts, and amenities online. Canary is the only PCI Level-1 Compliant solution for hotel authorizations. Schedule a demo today, and see how we can help your properties reduce chargebacks, save time, and improve the guest experience.

BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United States, Canada

Portfolio highlights

KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
Tolerance Bio — Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergi
Vittoria Biotherapeutics — Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.

Investment focus

Software, Biotechnology, Health Care
Series A, Series B, Series C
United States, United Kingdom, Israel

Portfolio highlights

Hermeus — Hermeus is developing hypersonic aircraft to connect the world faster than ever before.
CarTrade — CarTrade - Buy and Sell Used Cars in India at right price. Find New Cars, car prices, upcoming cars and images. Read latest auto news, reviews and car comparisons.
Matrimony.com — Revolutionizing the Indian matrimonial industry with world class matchmaking and wedding planning services. Your search for the perfect match ends here!

The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

Synthekine — Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory disease.
Atavistik Bio — Atavistik Bio is harnessing the power of protein-metabolite interactions to add a new lens to drug discovery.
Gritstone bio — Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. GritstoneOncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS.

Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.

Investment focus

Software, Information Technology, Internet
Series A, Seed, Series B
United States, United Kingdom, Brazil

Portfolio highlights

Granular — Corteva Agriscience software and digital solutions give the real-time, field-by-field information needed to maximize yield & manage input costs.
Databricks — Databricks offers a unified platform for data, analytics and AI. Build better AI with a data-centric approach. Simplify ETL, data warehousing, governance and AI on the Data Intelligence Platform.
Odyssey — Odyssey connects families with states to get access to funding from states to use with approved vendors to customize education for children who need it most.

KdT Ventures is the standard for early-stage frontier science investing.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Israel, Germany

Portfolio highlights

Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
PHNX Materials — PHNX Materials is a manufacturing company that specializes in turning waste into essential materials and reduce carbon emissions.
Faeth Therapeutics — Home | Faeth

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

Alumni Ventures is a venture capital firm that offers accredited investors access to diversified venture portfolios. The firm operates multiple funds, including alumni-focused and thematic funds, and co-invests alongside established venture firms. Investors can choose between fund-based investing or selecting individual deals. Alumni Venturesleverages a broad network to source capital, evaluate opportunities, and support portfolio companies. The firm manages a portfolio encompassing over 1,400 venture-backed companies across various sectors and stages.

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Series A, Series B
United States, United Kingdom, Canada

Portfolio highlights

MEDIVIS — Medivis is a leader in AR for healthcare, using augmented reality and artificial intelligence to advance medical imaging and surgical precision.
ZZ Driggs — ZZ Driggs is an award-winning company reimagining how we furnish our lives for a new economy and a more sustainable future. We offer exceptional, sustainable, and ethically-made heirloom-quality furniture to rent, buy, or both, made by the best independent & emerging designers today.
Mythical Games — We are Mythical Games, a Venture-backed next-generation game technology company at the intersection of video games and economics led by industry veterans.

At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Funding Round
United States, Israel, Canada

Portfolio highlights

Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
VeraDermics — VeraDermics Inc. is a dermatology pharmaceutical start-up, makers of WartPatch
PHȲND — PHȲND is a subscription-free cloud gaming platform that offers a way to discover, play, and socialize across a wide variety of games.

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Clarifai — Clarifai is the leading Machine Learning, Computer Vision, NLP Platform. Label, train, deploy models on one AI platform for developers & data scientists.
Mendaera — Mendaera enables all healthcare providers to perform precise and consistent point-of-care interventions. Their platform combines real-time imaging, robotics, and artificial intelligence to aid physicians in image acquisition and interpretation.
Primer — At Primer, we help organizations make the best use of their investment in data, by using best-in-class machine learning and natural language processing technologies.

WE BACK HEROES using technology to solve the world's biggest problems

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Germany, Canada

Portfolio highlights

Farcast — Unlocking satellite internet capacity through user terminal innovation
Solugen — Solugen's mission is to decarbonize the chemicals industry. Solugen combines synthetic biology with metal catalysis to make carbon negative chemicals at scale.Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with thecompetition.
Valence Discovery — Empowering drug discovery scientists with the latest advances in AI-enabled drug design

GV supports innovative founders moving the world forward.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Instawork — Instawork connects local businesses with proven hourly workers for temp, temp-to-hire shift work.
SingleStore — SingleStore is a provider of a database for operational analytics and cloud-native applications. It provides global enterprises with an intelligent database that works on any cloud on-premises or as a service runs transactions and analytics at the same time and lets clients promote their business through analytics and combine semi-structured datainto a consolidated big data platform.
Resistant AI — Resistant AI provides fraud detection and prevention in automated document processing workflows, transaction monitoring, and identities analysis.

We are deep tech venture capital.

Investment focus

Software, Artificial Intelligence, Machine Learning
Seed, Series A, Series B
United States, Canada, United Kingdom

Portfolio highlights

OraLiva — OraLiva is a lean startup focused to turning medical breakthroughs into real-world applications.
Radiant — Clean. Portable. Safe. Energy
Shennon Biotechnologies — Shennon Biotechnologies analyzes and manipulates a massive number of cells on the single-cell level to develop more effective treatments for human diseases. It functionally profiles millions of immune cells to find the best targets for cancer immunotherapy.

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Canada

Portfolio highlights

iRiva Medical — iRiva Medical is developing novel neuromodulation therapies to address unmet therapeutic requirements in large patient populations.
Viamet Pharmaceuticals — Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allowsthem to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
TetraLogic Pharmaceuticals — TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. ItsNecrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

Investing in early-stage companies solving the biggest science and engineering challenges since 2014.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Seed, Series B
United States, Austria, Switzerland

Portfolio highlights

Lightform — Lightform LFC Kit and LF2+ AR projector enable you to create light and sound experiences with sound-reactive projection mapping. Lightform brings projection mapping in reach for visual artists, designers, and other creatives.
TripleBlind — TripleBlind unlocks the estimated 105 petabytes of data stored by enterprises today that are inaccessible and not commercialized due to privacy concerns, operational complexity and regulation. The company’s patented breakthroughs in advanced mathematics enable organizations to privately share larger and more diverse data sets. Many high-valueapplications apply, such as innovating enhanced algorithms for medical diagnoses and improving anti-fraud initiatives for financial services. TripleBlind is the only technology that enables enterprises to rapidly commercialize data while maintaining compute performance; enabling all types of analysis on all data types, such as PII, PHI, genomic data, images, and confidential financial records. At the same time, the solution automatically enforces all international and regional data privacy standards including HIPAA, GDPR, PDPA and CCPA.TripleBlind is superior to existing solutions such as homomorphic encryption (slows compute performance), secure enclaves (siloes data), tokenization/masking/hashing and differential privacy (reduces accuracy), synthetic data (not real data), federated learning (limited use for algorithms), confidential computing (requires data centralization) and blockchain (not interoperable). Innovators such as Accenture, the Mayo Clinic and Snowflake trust TripleBlind to protect sensitive data. Please contact us for an overview, live demo or a one-hour, hands-on workshop.
MindImmune Therapeutics — Breaking through barriers to new therapeutics for brain disease.

With its purpose-driven culture and deep industry expertise, Frazier Healthcare is the preferred partner to profitable healthcare companies.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Post-IPO Equity
United States, Canada, Ireland

Portfolio highlights

PowerVision — PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clearvision at all distances.Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s.PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does.For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again.
Calibra Medical — Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.
Knipper Health — Knipper Health supports Pharma & Life Science Companies by Managing & Executing all Pharmaceutical Sampling & 3PL Services. Learn More!Knipper Health supports Pharma & Life Science Companies by Managing & Executing all Pharmaceutical Sampling & 3PL Services. Learn More!

Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Switzerland

Portfolio highlights

Triana Biomedicines — Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.
TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates
MindImmune Therapeutics — Breaking through barriers to new therapeutics for brain disease.

Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series A, Series C
United States, France, Switzerland

Portfolio highlights

Invitae — Invitae and Labcorp together offer advanced genetic testing that can be easily integrated into medical practices. Improve patient care with meaningful insights based on DNA.
Bolt Biotherapeutics — Bolt is leveraging the immune system for a better way to treat cancer. Our approach works with a person's body, not against it.
Vestagen Technical Textiles — Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in2009 and Based in Orlando, Florida.

Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they areknown by leaders of portfolio companies for the expertise and deep support they provide.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Funding Round, Series B
United States, Germany, Switzerland

Portfolio highlights

Sentieon — Sentieon develops a suite of bioinformatics secondary analysis tools that process genomics data with high computing efficiency and fast turnaround time.
Comet Therapeutics — CoEnzyme is a developer of therapies designed to treat orphan neurological disorders. The company develops a treatment to restore dysregulated CoEnzyme A metabolism through its CoEnzyme metabolism platform, enabling physicians to address the profound unmet medical needs.
Jupiter BioVentures — Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.

Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Seed, Series A
United States, Israel, The Netherlands

Portfolio highlights

Neurava — Neurava has developed wearable diagnostics for epilepsy patients including those at risk of SUDEP. The company specializes in the fields of medical device manufacturing, healthcare, and health diagnostics.
Flyte — Flyte promotes cellular healing in pelvic floor muscles for lasting results. Flyte is fast, proven, safe, pelvic floor therapy for bladder control.
Trio Pharmaceuticals — Trio Pharmaceuticals is a cancer therapeutics company that develops dual-action drugs for immunogenic tumors. These drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded in 2018 and is headquartered in San Diego, California.

Northpond Ventures is a science-driven venture capital ﬁrm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and aﬃliated industries.

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
Octave — Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.
Elephas — Elephas is a live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development.

DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, United Kingdom, Brazil

Portfolio highlights

Wyndly — Retrain your allergies through sublingual (under-the-tongue) treatment plans. Virtual appointments. Treatment delivered. Get started after your first consult with a board-certified doctor for $49.99.
Trial Library — At Trial Library, we partner with the oncology community to enable the discoverability of clinical trials for anyone, anywhere.
Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.

Boston Harbor Angels is a group of proven business leaders interested in investing a portion of their assets in high growth, early stage companies. The group was formed in February 2004 and since then has made a number of investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation,etc. They believe they contribute more than money to the companies they fund and welcome the opportunity to work with entrepreneurs open to take advice, yet having the smarts and determination to make the company successful.Their focus is on early stage companies usually looking to raise $250K to $1.5M, where they can fund a portion of the round and syndicate the deal with other angel groups or early stage venture funds. The stage of the company should be close to commercialization, while the company should have a clear and defensible competitive advantage. They are looking for capital efficient businesses, which can reach profitability with less than $5M of equity investment and provide at least 10X return on the investment within 5 years.They do not invest as a fund - each of their members makes his or her individual investment decision but they collaborate in Due Diligence. They have a deep expertise in the life sciences field where they usually take the position of a lead investor, but are open to any opportunities that can make a strong business case. In some cases they prefer to be the follow on investor if they cannot identify a person with strong expertise within their group.The groupâ€™s strategy is directed by an executive committee which consists of 8 people elected by the group: Wayne Griffith (chairman), Bill McPhee, Henry Kay, Jay Schwartz (membership director), Steve Andress, Peter Miller, Don Freeman and Mic Williams (president and founder). The groupâ€™s day-to-day operations are managed by Boris Batchvarov (managing director).They receive 20-30 business summaries each month, out of which they select 8 companies to make a personal presentation to their screening committee. The screening committee consists of volunteers from the group. The presentations are 10 min long followed by 10 min Q&A. 4 of the companies are invited to present to the whole group, with the idea to get the people interested and decide to perform a Due Diligence with the companies before making an investment.

Investment focus

Biotechnology, Health Care, Medical Device
Angel, Seed, Series A
United States, Canada, India

Portfolio highlights

Zylö Therapeutics — Patented technology that enables, for topicals, sustained release, increased druggability, a Patchless Patch concept, and enhanced targeting of pores and follicles
Xeno Biosciences — Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It wasfounded in 2015 and is headquartered in Somerville, Massachusetts.
Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.

INVESTMENT ADVISORS TO THE FIRST VC FUND DEDICATED TO BIOTECH INVESTMENT MANAGER OF 9 SUBSEQUENT BIOTECH VC FUNDS

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Canada, Estonia

Portfolio highlights

Epic Sciences — Epic Sciences develops clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer.
Antios Therapeutics — This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger
Fractyl Health — Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.

Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Canada, United Kingdom

Portfolio highlights

Casma Therapeutics — Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
Feldan Therapeutics — Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle.
Mindset Medical — Mindset Medical is a Health Care Company that develops a platform for clinical information. Through their platform physicians will understand patient pain, saves time for providers and patients, they eliminate paper and redundant forms, and allows providers more time for patients. Mindset Medical was founded in 2016 in Phoenix, Arizona.

Refactor Capital is an early-stage venture capital firm that invests in founders solving fundamental human problems.

Investment focus

Health Care, Biotechnology, Medical
Seed, Series A, Series B
United States, United Kingdom, New Zealand

Portfolio highlights

Pilgrim — Pioneering a biologically enhanced future for humanity.
Causal Labs — Causal Labs provides AI physics models to predict and control the weather.
Remedy Scientific — Remedy decontaminates land with scalable, AI-driven systems, advanced chemistry and precise sensors, restoring sites to their full productive potential.

Novo Holdings is a holding company specializing in life science investors with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

Founders Fund is a San Francisco based venture capital firm investing in companies building revolutionary technologies.

Investment focus

Software, Health Care, Information Technology
Series A, Seed, Series B
United States, United Kingdom, Germany

Portfolio highlights

Newfront — Modern insurance platform transforming risk management, employee experience, insurance, and retirement solutions with transparent data to lower your total cost of risk.
Nubank — Nubank issues, administrate, processes, and transfers payments related to post-paid credit cards and equity investment in other entities. It serves clients in Brazil. The company launched its proprietary loyalty rewards program ("Nubank Rewards"), as well as a digital account ("NuConta") that is already used by more than 17million people.Cristina Junqueira, David Velez, and Edward Wible founded EO2 Solucoes de Pagamento on May 6, 2013 that became Nubank in on June 25, 2013. It has its headquarters in São Paulo in Brazil.
Vest — Vest is an app-based brokerage that wants to provide Latin American savers with access to American assets that are differentiated by product, pricing, and content. Latin Americans are known for saving, but many prefer to do so in cash or in zero-interest savings accounts.

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

IFM Therapeutics — IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of thecGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis
Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
Scorpion Therapeutics — We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.

The North Carolina Biotechnology Center is a private, non-profit corporation funded by the N.C. General Assembly to strengthen biotechnology research, business and education statewide. The Center is not a site for laboratory research; it works to support job creation in the biotechnology industry.

Investment focus

Biotechnology, Health Care, Medical
Debt Financing, Grant, Funding Round
United States, United Kingdom

Portfolio highlights

Phase — Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
QATCH Technologies — Get the most out of a drop
Atlantic Fish Company — Atlantic Fish Co is a cultivated seafood company using cellular agriculture to bring the world sustainable delicious seafood.

Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.

The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series C, Post-IPO Equity
United States, China, United Kingdom

Portfolio highlights

CAMP4 Therapeutics — CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients.
Trevi Therapeutics — Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
Chentai New Materials — Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products.

We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Canada, United Kingdom

Portfolio highlights

Lila Sciences — Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation.
Terrana Biosciences — Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions.
Expedition Medicines — Defining a new era in drug discovery where chemistry rewrites the rules of biology to engage any protein target.

DCVC backs companies using deep tech to solve the biggest problems that matter. Our investments address climate change, human health, the operations of physically intensive industries, defense, security, space, and more.

Investment focus

Biotechnology, Therapeutics, Medical
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
Valar Labs — AI to Make Oncologists Smarter
Radionetics Oncology — Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is poised to capitalize on the increasing demand for novel radiotherapeutics.

Lilly is a medicine company that puts health above all. Learn about our medicines, view condition support, find care, and much more.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
United States, United Kingdom, Canada

Portfolio highlights

Excelsior Sciences — Rebuilding the World, From the Bottom Up
Syndeio Biosciences — Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders.
Affinia Therapeutics — Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines for people.

Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, France, China

Portfolio highlights

Leyden Labs — Leyden Labs helps people live freely by developing products that protect from known and new respiratory viruses.
Octave — Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.
Auron Therapeutics — A differentiated approach to cure cancer.

Investors by industry

Community

Artificial intelligence